Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

NCT04550442 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Chronic Myelomonocytic Leukemia
Refractory Myelodysplastic Syndrome
Therapy-Related Myelodysplastic Syndrome

Interventions

DRUG: Azacitidine
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]